Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML

Background Acute myeloid leukemia (AML) stem cells (LSCs) are capable of surviving current standard chemotherapy and are the likely source of deadly, relapsed disease. While stem cell transplant serves as proof-of-principle that AML LSCs can be eliminated by the immune system, the translation of exi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	R Eric Davis, Marina Konopleva, Natalia Baran, Gheath Al-Atrash, Naval Daver, Shelley Herbrich, Tianyu Cai, Connie Weng, Marisa J L Aitken, Sean M Post, Jared Henderson, Chunhua Shi, Guillame Richard-Carpentier, Guy Sauvageau, Keith Baggerly, Dongxing Zha, Ondrej Havranek
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ec9bd9e5fbea4ec3b2a31d083604c1bd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML

Ejemplares similares